 |
| Apollo's future bright as Board gathers Moss |
Bill Moss AM | Apollo Life Sciences' value and profile have received a recent boost, with the appointment of high-profile Macquarie Bank executive Bill Moss AM as a non-executive director.
Mr Moss, who leads Macquarie Bank's Banking and Property Group, has also invested $2 million in Apollo.
Mr Moss' involvement is a strong signal of confidence in Apollo as an ongoing investment prospect.
"Part of the excitement about investing in a start-up biotech company is that you can be part of some pretty radical change if it is successful," he said.
"With investment there are opportunities to pick products that are going to be world-class leaders. If you can get them right you'll get an outstanding return. That is what I hope I'll get with Apollo."
As well as Apollo's potential as a start-up company, Mr Moss was attracted by the products under development - particularly the delivery of medicines orally and through the skin rather than by injection.
"Apollo has been working on initiatives that can change the way we look at traditional medicine," he said.
Mr Moss says Apollo's viability is enhanced by its strategy of raising early income from cosmetics and medical research products, to finance ongoing therapeutic product development.
"Apollo is unique because it has a multi-dimensional product range. Apollo has the ability to have more than a single source of cash flow.
"That is one of the exciting opportunities for this company while it is in the early development stages."
Apollo will benefit from Mr Moss's expertise in new venture development.
"With my background in international business and finance I am hoping I can bring some of those skills to the board," he said. |
|
|
| click to subscribe |
|
 |
| www.apollolifescience.com |
